^
    over2years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28
    over2years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Initiation date: Nov 2021 --> Mar 2022 | Trial primary completion date: Mar 2023 --> Oct 2023
    Trial initiation date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28
    3years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P2 trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28